Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LCAT | P04180 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26702781 | 0.89 | LMNA (0.51) | ACACBPANK3LMNAKDM4EABL1 | |
| SCHEMBL10141652 | 0.82 | LCAT (0.47) | ACACBPANK3MAPTLCATHRH3 | |
| SCHEMBL16648668 | 0.82 | USP30 (0.53) | KDM4EMAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL20152892 | 0.81 | HRH3 (0.53) | PANK3LMNAKDM4EABL1MAPT | |
| SCHEMBL15247289 | 0.81 | LCAT (0.46) | ACACBPANK3LMNATP53MAPT | |
| SCHEMBL10141629 | 0.81 | MAPT (0.55) | ACACBPANK3LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16769743 | 0.80 | HRH3 (0.48) | ACACBLMNAKDM4EABL1LCAT | |
| SCHEMBL10136514 | 0.80 | PANK3 (0.57) | ACACBPANK3LMNAKDM4EMAPT | |
| SCHEMBL16769733 | 0.80 | HRH3 (0.55) | LMNAKDM4EABL1MAPTSMN1; SMN2 | |
| SCHEMBL16769732 | 0.80 | GPR119 (0.53) | PANK3LMNAKDM4EABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | ACACB 209/4885PANK3 1183/4885LMNA 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.